Laboratorio de Microbiología General, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, Mexico.
Servicio de Gastroenterología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Mexico.
Biomed J. 2022 Feb;45(1):200-205. doi: 10.1016/j.bj.2021.02.007. Epub 2021 Feb 23.
Clostridium difficile infection (CDI) is a leading cause of healthcare-associated diarrhea worldwide. In this study, risk factors associated with the development of severe-complicated and recurrent outcomes in CDI patients in different age groups, including the non-elderly, were assessed in a third-level hospital.
CDI cases were detected by clinical data and polymerase-chain-reaction (PCR). Clinical, demographic, epidemiological, and microbiological risk factors for CDI were evaluated.
During the study period, 248 out of 805 patients with nosocomial diarrhea were diagnosed with CDI and the majority were severe-complicated cases (87.90%). Female gender (OR 3.19, 95% CI 1.19-8.55, p = 0.02) and lymphoma (OR 3.95, 95% CI 1.03-15.13, p = 0.04) were risk factors for severe-complicated CDI. Mature adulthood (51-60 years) (OR 5.80, 95% CI 1.56-21.62, p = 0.01), previous rifampicin use (OR 7.44, 95% CI 2.10-26.44, p = 0.00), and neoplasm (solid malignant neoplasm or hematological malignancies) (OR 4.12, 95% CI 1.01-16.83, p = 0.04) were risk factors for recurrent infection. Autoimmune disorders (OR 6.62, CI 95% 1.26-34.73, p = 0.02), leukemia (OR 4.97, 95% CI 1.05-23.58, p = 0.04), lymphoma (OR 3.79, 95% CI 1.03-12.07, p = 0.04) and previous colistin treatment (OR 4.97, 95% CI 1.05-23.58, p = 0.04) were risk factors for 30-day mortality.
Newly identified risk factors for recurrent CDI were rifampicin treatment and age between 51 and 60 years; colistin treatment was identified as a risk factor for 30-day mortality. Previously identified risk factors for severe-complicated CDI were confirmed, but with a major impact on non-elderly patients.
艰难梭菌感染(CDI)是全球范围内导致医疗保健相关腹泻的主要原因。在这项研究中,评估了三级医院中不同年龄段(包括非老年)CDI 患者发生严重并发症和复发结局的相关危险因素。
通过临床数据和聚合酶链反应(PCR)检测 CDI 病例。评估了与 CDI 相关的临床、人口统计学、流行病学和微生物学危险因素。
在研究期间,805 例住院腹泻患者中有 248 例被诊断为 CDI,其中大多数为严重并发症病例(87.90%)。女性(OR 3.19,95%CI 1.19-8.55,p=0.02)和淋巴瘤(OR 3.95,95%CI 1.03-15.13,p=0.04)是严重并发症 CDI 的危险因素。成年中期(51-60 岁)(OR 5.80,95%CI 1.56-21.62,p=0.01)、既往利福平治疗(OR 7.44,95%CI 2.10-26.44,p=0.00)和肿瘤(实体恶性肿瘤或血液恶性肿瘤)(OR 4.12,95%CI 1.01-16.83,p=0.04)是复发感染的危险因素。自身免疫性疾病(OR 6.62,95%CI 1.26-34.73,p=0.02)、白血病(OR 4.97,95%CI 1.05-23.58,p=0.04)、淋巴瘤(OR 3.79,95%CI 1.03-12.07,p=0.04)和既往粘菌素治疗(OR 4.97,95%CI 1.05-23.58,p=0.04)是 30 天死亡率的危险因素。
新发现的复发性 CDI 的危险因素是利福平治疗和 51-60 岁之间的年龄;粘菌素治疗被确定为 30 天死亡率的危险因素。先前确定的严重并发症 CDI 的危险因素得到了证实,但对非老年患者的影响更大。